Litigation Details for Takeda Pharmaceuticals U.S.A., Inc. v. Hikma Pharmaceuticals USA, Inc. (D. Del. 2014)

Takeda Pharmaceuticals U.S.A., Inc. v. Hikma Pharmaceuticals USA, Inc. (D. Del. 2014)

Docket		Date Filed	2014-10-03
Court	District Court, D. Delaware	Date Terminated	2018-12-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Plaintiff	Referred To	Sherry R. Fallon
Parties	HIKMA PHARMACEUTICALS PLC
Patents	6,037,157; 7,601,758; 7,619,004; 7,820,681; 7,906,519; 7,915,269; 7,935,731; 7,964,647; 7,964,648; 7,981,938; 8,093,297; 8,097,655; 8,415,395; 8,440,722
Attorneys	Heather E. Takahashi
Firms	Law Office of Michael R. Abram
Link to Docket	External link to docket

Details for Takeda Pharmaceuticals U.S.A., Inc. v. Hikma Pharmaceuticals USA, Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-03				External link to document

Takeda v. Hikma Pharmaceuticals Patent Litigation Summary, 1:14-cv-01268

Last updated: August 2, 2026

Takeda Pharmaceuticals U.S.A., Inc. sued Hikma Pharmaceuticals USA, Inc. in the U.S. District Court for the District of Delaware over Hikma’s abbreviated new drug application for generic colchicine 0.6 mg tablets, the generic counterpart to Takeda’s Colcrys product. The dispute involved method-of-use and formulation patents listed for Colcrys. The case ended without a publicly reported merits judgment establishing that Hikma’s proposed product infringed valid claims. The docket was terminated after resolution of the dispute, and the commercial terms were not publicly disclosed in the court record. [1]

What drug and ANDA were involved in Takeda v. Hikma?

The litigation concerned colchicine tablets, 0.6 mg, marketed by Takeda as Colcrys.

Item	Information
Brand product	Colcrys
Active ingredient	Colchicine
Dosage form	Oral tablet
Strength	0.6 mg
Reference sponsor	Takeda Pharmaceuticals U.S.A., Inc.
Generic applicant	Hikma Pharmaceuticals USA, Inc., formerly associated with West-Ward Pharmaceuticals
Regulatory pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-01268
Judge	Richard G. Andrews
Filing year	2014
Case disposition	Terminated following resolution of the dispute

Colchicine is used for acute gout flares, gout prophylaxis, and familial Mediterranean fever. Colcrys received FDA approval in 2009 after Takeda submitted clinical and pharmacokinetic data supporting a lower-dose regimen than older colchicine products. [2]

What patents protected Colcrys in the Hikma litigation?

The case involved patents covering colchicine dosing, treatment methods, and related product technology. The principal Colcrys patent estate included the following patents:

Patent	General subject matter	Reported expiration
U.S. Patent No. 7,582,621	Methods of treating gout with colchicine	October 2, 2028
U.S. Patent No. 7,619,004	Colchicine treatment methods, including gout-related dosing	October 2, 2028
U.S. Patent No. 8,598,219	Colchicine compositions and methods of use	May 11, 2032

The asserted scope depended on the specific claims, the language of Hikma’s ANDA, the proposed labeling, and Takeda’s infringement contentions. The central commercial protection for Colcrys was the dosing regimen patent protection extending beyond the product’s initial regulatory exclusivity period.

Patent expiration dates in Orange Book records can differ from the basic twenty-year patent term because of patent-term adjustment, patent-term extension, disclaimers, terminal disclaimers, or later Orange Book corrections. The FDA Orange Book remains the controlling commercial reference for listed drug patents and exclusivity information. [3]

What was Takeda’s infringement theory?

Takeda’s case was based on the Hatch-Waxman artificial-infringement provisions. Hikma’s filing of an ANDA with a Paragraph IV certification allegedly created an act of infringement under 35 U.S.C. § 271(e)(2).

Takeda’s principal theories were:

1. Hikma’s proposed colchicine product would be used according to labeling that practiced patented gout-treatment methods.
2. Hikma’s proposed product would be commercially substituted for Colcrys and would induce physicians, pharmacists, or patients to practice the claimed methods.
3. The ANDA product and proposed labeling would meet the limitations of Takeda’s colchicine treatment and dosing claims.
4. The asserted claims were valid and enforceable against Hikma’s generic product.

Method-of-use litigation often turns on the proposed label rather than the chemical identity of the active ingredient. A generic applicant can avoid infringement by carving out patented indications or dosing instructions when the FDA-approved label permits a legally adequate skinny label. The analysis becomes more difficult when the patented regimen is embedded in the principal use of the drug or is difficult to remove without affecting safety or efficacy information.

How did Hikma challenge the Colcrys patents?

Hikma’s Paragraph IV position placed validity, enforceability, and infringement in dispute. The expected defenses in the case included:

• Lack of infringement based on the ANDA product or proposed label.
• Invalidity for anticipation or obviousness.
• Lack of written description or enablement, where applicable.
• Improper claim scope for the proposed dosing regimen.
• Possible noninfringement based on labeling carve-outs.
• Challenges to the connection between the claimed method and the generic product’s intended use.

The strongest generic defense in a colchicine method case is usually noninfringement based on label design. If the proposed generic label omits a patented use and the remaining instructions do not encourage the patented method, the ANDA applicant may reduce induced-infringement exposure. Takeda’s counterargument would be that the complete label, prescribing environment, or product design still encourages performance of the claimed regimen.

What was the litigation timeline?

Date	Event
2009	FDA approved Colcrys for specified colchicine indications. [2]
2014	Takeda filed the Delaware patent action against Hikma.
2014-2016	The parties litigated infringement, validity, claim construction, and related Hatch-Waxman issues.
2016	The case was resolved and terminated on the district court docket.
2016 onward	FDA approvals for generic colchicine products increased competitive pressure on Colcrys.

The public record does not establish a reported final judgment holding Hikma’s ANDA product to infringe valid and enforceable claims. The case therefore differs from a fully litigated Hatch-Waxman matter producing a public injunction date or a Federal Circuit merits ruling.

What was the settlement status in Takeda v. Hikma?

The case ended through resolution rather than a reported merits decision. Public docket materials do not disclose the principal business terms, including any potential license date, launch date, royalty rate, authorized-generic arrangement, or restriction on Hikma’s commercialization.

That distinction matters for market-entry analysis. A case termination does not, by itself, establish:

• That the asserted patents were invalid.
• That Hikma obtained an immediate right to launch.
• That Takeda granted a license covering every Colcrys patent.
• That all Orange Book-listed patents were resolved.
• That the settlement applied to other generic applicants.

A settlement can resolve the particular defendant’s litigation while leaving later-filing ANDA applicants exposed to separate litigation or separate settlement terms.

When did Colcrys lose FDA exclusivity?

Colcrys’ principal market protection came from a combination of FDA exclusivity and patents.

Protection	Commercial effect
New drug exclusivity	Delayed certain competing FDA approvals after the 2009 approval
Orange Book patents	Created potential stay and litigation rights against Paragraph IV ANDA filers
Method-of-use patents	Protected dosing and treatment instructions rather than colchicine itself
Formulation and composition patents	Potentially covered product configuration or related colchicine technology

FDA exclusivity and patent protection operate independently. FDA exclusivity can expire while a patent remains enforceable. Conversely, an unexpired patent may not prevent approval if the generic applicant makes a successful Paragraph IV showing, uses a permissible label carve-out, or reaches a settlement with the patent holder.

What was the Orange Book status of Colcrys?

Colcrys was listed in the FDA Orange Book with patents covering colchicine treatment methods and related product technology. The Orange Book listings were important because they allowed Takeda to invoke the Hatch-Waxman litigation framework after receiving a Paragraph IV certification.

Orange Book status should be analyzed at the patent-and-claim level. A listed method-of-use patent does not necessarily block all generic sales. Its practical effect depends on:

• The indication associated with the listed patent.
• The language of the generic label.
• Whether the generic product can be marketed with a carve-out.
• Whether the patent is still enforceable.
• Whether pediatric exclusivity or patent-term adjustment changes the effective date.
• Whether the generic applicant prevails on validity or infringement.

How strong was Takeda’s patent estate?

Takeda’s estate was commercially meaningful but structurally narrower than a compound patent estate.

Strengths

• The principal patents extended well beyond the 2009 FDA approval date.
• Colchicine had a defined dosing regimen that supported method-of-use claims.
• The patents could trigger Hatch-Waxman litigation and delay approval or launch.
• Colcrys’ label gave Takeda a factual basis for induced-infringement arguments.
• The patents covered clinically relevant uses rather than only peripheral manufacturing processes.

Limitations

• Colchicine itself was an old active ingredient and did not have a new-molecule patent barrier.
• Method-of-use claims can be avoided through label carve-outs.
• Generic applicants can challenge the validity of dosing claims using prior clinical and pharmacological disclosures.
• A product patent covering the active ingredient was unavailable as the principal barrier.
• Multiple generic applicants could create separate litigation and settlement pathways.

The estate was therefore stronger as a regulatory and litigation barrier than as an absolute monopoly over colchicine.

What generic entry risks existed for Takeda?

The main risks were early generic approval, label-based noninfringement, and settlement-driven entry.

Risk	Effect on Takeda
Paragraph IV challenge	Required litigation or acceptance of generic risk
Skinny-label approval	Could allow generic entry for unpatented indications
Invalidity ruling	Could remove the principal patent barrier before expiration
Noninfringement ruling	Could permit entry without invalidating the patents
Multiple ANDA filers	Increased price erosion and litigation expense
Authorized generic launch	Could protect volume but accelerate price compression
Settlement	Could preserve patent validity while conceding a negotiated entry date

Colchicine’s genericization risk was higher than for a product protected by an unexpired compound patent. Once FDA-approved generic colchicine products reached the market, Takeda faced substitution and reimbursement pressure even if some later-expiring patents remained listed.

Which companies challenged or competed with Colcrys?

The Colcrys patent program generated litigation involving multiple generic applicants, including Hikma and other ANDA sponsors. Generic colchicine competition also came from companies whose products were approved after the FDA’s regulatory exclusivity and patent disputes were addressed.

The competitive landscape included:

• Hikma Pharmaceuticals USA.
• West-Ward Pharmaceuticals, the predecessor or related operating entity associated with Hikma’s U.S. generic business.
• Other ANDA applicants pursuing colchicine 0.6 mg tablets.
• Authorized-generic channels associated with the brand sponsor.
• Established colchicine products and alternative gout therapies.

Competition was driven by substitution economics because colchicine tablets are relatively simple oral solid dosage forms. The principal barriers were regulatory approval, patent risk, manufacturing compliance, and commercial contracting rather than complex biologic manufacturing.

What manufacturing and intellectual-property barriers remained?

Manufacturing barriers were moderate. Colchicine does not require biologic production, sterile fill-finish, or a complex delivery device. A generic manufacturer still needed:

• Demonstrated pharmaceutical equivalence.
• Bioequivalence data.
• Validated content uniformity and dissolution controls.
• Compliance with current good manufacturing practices.
• Reliable supply of colchicine active pharmaceutical ingredient.
• A label that did not improperly practice asserted method claims.

The remaining intellectual-property barriers were concentrated in method-of-use, composition, and formulation claims. Manufacturing-process patents could affect a supplier or production route, but they were less likely than the listed Colcrys method patents to control ordinary generic commercialization.

What was the commercial impact of the case?

The litigation protected Takeda’s ability to negotiate over the timing and terms of generic entry, but it did not create a permanent barrier to colchicine competition. Colcrys faced structural revenue exposure because:

1. The active ingredient was old.
2. The product was an oral tablet.
3. Multiple generic applicants could pursue approval.
4. Method-of-use patents were vulnerable to label-based strategies.
5. Generic substitution could produce rapid price erosion after entry.

The commercial value of the litigation depended less on preserving exclusivity through the full patent term than on controlling the first generic launch, negotiating launch timing, and managing authorized-generic competition.

Key Takeaways

• Takeda sued Hikma in Delaware over an ANDA for generic colchicine 0.6 mg tablets.
• The dispute centered on Colcrys method-of-use and related colchicine patents.
• Principal patents associated with the estate included U.S. Patent Nos. 7,582,621, 7,619,004, and 8,598,219.
• The case ended through resolution rather than a reported merits judgment against Hikma.
• Public docket materials do not disclose the commercial settlement terms.
• Takeda’s patent position was meaningful but narrower than a compound patent estate because colchicine was an old active ingredient.
• Generic entry risk remained high because method-of-use claims can be challenged through label carve-outs and noninfringement theories.
• The case did not, by itself, establish the launch date or market rights for every generic colchicine applicant.

FAQs About Takeda v. Hikma, 1:14-cv-01268

Did Hikma win the Colcrys patent case?

The public record does not show a reported merits judgment declaring Hikma’s ANDA product noninfringing or the asserted patents invalid. The case was resolved and terminated.

What is the expiration date of Takeda’s main Colcrys patent?

U.S. Patent No. 7,582,621 is generally reported with an expiration date of October 2, 2028. The effective commercial date must be checked against the current Orange Book record and any applicable statutory adjustments.

Did Takeda have a compound patent on colchicine?

No. Colchicine is an old active ingredient. Takeda’s principal protection relied on dosing, treatment-method, composition, and related product patents.

Could a generic company sell colchicine for an indication covered by a Takeda patent?

Potentially. A generic applicant could seek approval with a label carve-out or prevail on noninfringement, but the outcome would depend on the patent claims, proposed label, and litigation record.

Does termination of the case prove that Hikma could immediately launch?

No. Case termination alone does not establish an immediate launch right. Launch timing would depend on the settlement, FDA approval status, Orange Book patents, regulatory exclusivity, and any continuing contractual restrictions.

References

1. U.S. District Court for the District of Delaware. (2014). Takeda Pharmaceuticals U.S.A., Inc. v. Hikma Pharmaceuticals USA, Inc., No. 1:14-cv-01268-RGA. PACER docket record.

2. U.S. Food and Drug Administration. (2009). Colcrys approval letter and prescribing information. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.